Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

Linda Liau responds to investor concerns regarding 12/15/16

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (20) | Next 10 | Previous | Next
sentiment_stocks Member Profile
Member Level 
Followed By 132
Posts 12,195
Boards Moderated 1
Alias Born 03/29/14
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/26/2021 4:55:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/19/2021 4:07:42 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 1/15/2021 7:21:09 AM
The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think InvestorsHub NewsWire - 1/7/2021 8:00:00 AM
Biotech Companies; Recent Milestones and Potential Upside InvestorsHub NewsWire - 12/22/2020 8:05:00 AM
TNS is on the Hunt for the Next OTC Home Run Stock, Feature Report InvestorsHub NewsWire - 11/30/2020 8:20:00 AM
Immune Therapeutics, Inc. Spinoff Cytocom, Inc. Appoints BioPharm Industry Veteran as New Chief Operating Officer InvestorsHub NewsWire - 11/11/2020 9:11:00 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/10/2020 4:58:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/2/2020 2:16:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:59:18 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/13/2020 9:31:10 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 9/15/2020 5:14:31 PM
SA Breaking News: ALYI - Alternet Systems revenue surging with new potential customers InvestorsHub NewsWire - 9/14/2020 10:10:04 AM
Traders News Source Identifies Tomorrows NASDAQ's InvestorsHub NewsWire - 9/3/2020 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/1/2020 3:24:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/20/2020 4:52:41 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 4:44:16 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/7/2020 5:27:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/26/2020 5:07:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/24/2020 6:02:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/8/2020 5:02:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2020 5:12:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/29/2020 5:28:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/27/2020 5:15:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2020 5:06:06 PM
sentiment_stocks Member Level  Monday, 12/19/16 11:54:18 AM
Re: None
Post # of 357953 
Linda Liau responds to investor concerns regarding 12/15/16 Seattle presentation. In an email exchange between an investor and Linda Liau, Dr. Liau offers clarification regarding her comments from the presentation.

Quote:

Question
Dear Dr. Liau: In your video last week (and also last year), your comments seemed quite positive about the patients living longer, but last week you also seemed to say that DCVax would not be able to get FDA approval. Is that what you really meant? How could that be the case if patients are living longer? Would love to have clarification on this issue

Thank you in advance for your time .
Xxxxxx xxxxxxxx


Dr. Liau's answer

Hi Xxxxxx,

Yes, the patients do seem to be living longer with DCVax; and no, I did not mean to say that DCVax would not get FDA approval. I was making the point that, whether or not the study fits a particular category endpoint, there should be a way to get approval if the data shows that the entire group of DCVax patients (in both arms) does better than concurrent/historical controls who have not gotten DCVax.

Hope this clarifies the issue.

Thanks,
LL


Linda M. Liau, M.D., Ph.D., M.B.A.
Professor & Vice Chair of Neurosurgery

Director, UCLA Brain Tumor Program

UCLA Department of Neurosurgery
Sent from my iPhone




This investor doesn’t post on the boards, and decided to forward me the above email exchange with Dr. Liau regarding a question the investor had asked her in an email. The investor was concerned as a result of her Seattle presentation that Linda Liau was of the impression that DCVax-L would not be eligible for FDA approval despite the fact that these patients were all living longer.

Dr. Liau’s response to the query is important, and I don’t believe this person had actually anticipated receiving a response from her, let alone a response as quickly as it was given.

So this person forwarded the entire query and response to me because this investor felt what Dr. Liau wrote was very relevant to all other investors as well. And since this investor knows I do post on the boards, this seemed the best way to share it.

And I know a few of you will wonder why this person couldn’t just post it themselves. The answer is that this investor doesn’t post, has never posted, and most of you would not be familiar with this person anyway. The investor decided that having me post this exchange with Dr. Liau would be the best way to get out LL’s self-described clarification on this “issue” to all of us.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (20) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences